ZARONTIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZARONTIN (ZARONTIN).
Ethosuximide (Zarontin) suppresses paroxysmal 3 Hz spike-and-wave activity associated with absence seizures. The mechanism may involve inhibition of T-type calcium channels in thalamic neurons, reducing oscillatory burst firing.
| Metabolism | Ethosuximide is extensively metabolized in the liver, primarily via cytochrome P450 enzymes (CYP3A4) to inactive metabolites. Approximately 20% is excreted unchanged in urine. |
| Excretion | Renal: ~40% as unchanged drug; hepatic metabolism accounts for ~60% (primarily via CYP3A4, forming inactive metabolites); <1% fecal. |
| Half-life | 60 hours (range 40-70) in adults; 30-40 hours in children (due to higher clearance); clinical context: steady-state reached in ~10-14 days; may be reduced with enzyme-inducing co-medications. |
| Protein binding | ~90% bound to albumin; saturable at high concentrations, leading to increased free fraction. |
| Volume of Distribution | 0.5 L/kg; moderate distribution, primarily in total body water; crosses placenta and appears in breast milk (concentration ~50% of maternal serum). |
| Bioavailability | Oral: ~98% (near complete absorption); no parenteral formulation available. |
| Onset of Action | Oral: 2-4 hours (peak serum concentration); therapeutic effect (seizure control) may require 1-2 weeks of daily dosing. |
| Duration of Action | Oral: ~24 hours (serum levels maintained with once- or twice-daily dosing); clinical duration (seizure protection) extends throughout dosing interval due to long half-life. |
| Molecular Weight | 212.25 |
500 mg orally twice daily initially; may increase by 250 mg every 4-7 days. Maintenance: 1000-1500 mg/day in 2 divided doses; maximum 1500 mg/day.
| Dosage form | CAPSULE |
| Renal impairment | No specific dose adjustment guidelines; caution with severe impairment (GFR <30 mL/min) due to possible accumulation; consider monitoring levels. |
| Liver impairment | No specific Child-Pugh based guidelines; use with caution in severe hepatic impairment. |
| Pediatric use | Age 3-6 years: 250 mg orally once daily initially; increase by 250 mg every 4-7 days. Maintenance: 500-750 mg/day in 2 divided doses. Age 6-16 years: 500 mg orally once daily initially; increase similarly. Maximum: 1000 mg/day. |
| Geriatric use | Start at lower end of dosing range (500 mg/day) due to age-related decline in renal function; monitor renal function and adjust accordingly. |
| 1st trimester | Known teratogen; associated with increased risk of major congenital malformations including neural tube defects, cleft lip/palate, and cardiac defects. Avoid use unless no safer alternative. |
| 2nd trimester | May cause fetal growth restriction and other adverse effects. Use only if benefits outweigh risks. |
| 3rd trimester | Neonatal withdrawal syndrome possible. Use with caution. |
Clinical note
Comprehensive clinical and safety monograph for ZARONTIN (ZARONTIN).
| Placental transfer | Crosses placenta readily; fetal concentrations approximate maternal levels. |
| Breastfeeding | Excreted into breast milk with reported infant serum levels reaching therapeutic range. Monitor infant for sedation, poor feeding, and weight loss. Benefits must outweigh risks. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to ethosuximide or succinimidesPorphyria
| Precautions | May cause blood dyscrasias including agranulocytosis, aplastic anemia, and pancytopenia; monitor CBC at baseline and periodically., Systemic lupus erythematosus (SLE)-like syndrome has been reported., Suicidal ideation and behavior; monitor for depression or mood changes., May impair cognitive and motor function; caution with driving or operating machinery. |
| Food/Dietary | Take with food to reduce gastrointestinal upset. Alcohol may increase central nervous system depression; avoid concurrent use. No specific food restrictions. |
Loading safety data…
| Lactation Rating |
| L4 (Possibly Hazardous) |
| Teratogenic Risk | First trimester: Increased risk of major congenital malformations, particularly neural tube defects, cleft lip/palate, and cardiac defects. Second and third trimesters: Risk of fetal hydantoin syndrome, including growth restriction, dysmorphic facial features, and neurodevelopmental impairment. Antiepileptic drugs in general increase risk; use lowest effective dose, consider folic acid supplementation. |
| Fetal Monitoring | Monitor serum ethosuximide levels every 4-6 weeks during pregnancy due to altered pharmacokinetics. Perform fetal ultrasound for anomaly detection at 18-20 weeks. Consider prenatal vitamin K supplementation in third trimester to prevent neonatal hemorrhagic disease. Postnatal: monitor infant for withdrawal symptoms, sedation, and poor feeding. |
| Fertility Effects | No well-documented adverse effects on fertility. Antiepileptic drugs may affect hormonal balance; data limited. Consult reproductive endocrinology if fertility issues arise. |
| Clinical Pearls |
| Zarontin (ethosuximide) is the drug of choice for absence seizures. Monitor for behavioral changes, especially aggression or psychosis. CBC and liver function tests should be performed periodically due to risk of blood dyscrasias and hepatic toxicity. Dose titration is slow; therapeutic serum levels are 40-100 mcg/mL. |
| Patient Advice | Take this medication exactly as prescribed; do not stop abruptly. · Report any unusual bleeding, bruising, or signs of infection immediately. · Avoid driving or operating machinery until you know how Zarontin affects you. · Contact your doctor if you experience mood changes, depression, or suicidal thoughts. · Use effective contraception if of childbearing potential; discuss pregnancy plans with your doctor. |